Adobe's Blockbuster...
Health Care: Drugs
Tekmira Pharmaceuticals Corporation (TKMR: NASDAQ)
$4.76 -0.02 | -0.42%
06/19/13 - 03:04 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 4.76 |
| 52 Week High | 6.78 |
| 52 Week Low | 1.96 |
| Avg. Daily Vol. (Mil) | 0.07 |
| Beta (3 year) | 0.72 |
| Share Related Items | |
| Mkt Cap (Mil) | 68.49 |
| Shares Out (Mil) | 14.39 |
| Float (Mil) | 13.52 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.60 |
| Current Ratio | 4.00 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | 2.20 |
| Price/Sales | 5.44 |
| Price/Book | 1.81 |
| Price/Cash Flow | 2.20 |
| Per Share Data | |
| Earnings | 2.16 |
| Sales | 0.87 |
| Book Value | 2.64 |
| Cash Flow | 2.19 |
| Business Summary | |
|---|---|
| Tekmira Pharmaceuticals Corporation develops ribonucleic acid interference therapeutic product candidates as well as provides its lipid nanoparticle delivery technology to pharmaceutical partners in the Canada. | |
| General Information | |
| 8900 Glenlyon Parkway
Suite 100 Burnaby, BC V5J 5J8 |
|
| www.tekmirapharm.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 57 | |
| CEO: Dr. Mark J. Murray,PhD | |
| Short Interest | |
| Current Month (Mil) | 0.01 |
| Previous Month (Mil) | 0.01 |
| Short Interest Ratio (Days) | 0.20 |
| Management Effectiveness | |
| Return on Equity | 80.90 |
| Return on Assets | 60.60 |
| Return on Investments | 80.90 |
| Profitability | |
| Gross Margin | -42.00 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with TKMR
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
Latest TKMR Headlines from TheStreet
- Tekmira Announces Election Of Directors 05.17.13 | 06:05 pm
- Tekmira Presents LNP Technology Innovations At Scientific Symposium 05.15.13 | 04:05 pm
- Tekmira Provides Corporate Update And Announces First Quarter 2013 Results 05.14.13 | 04:05 pm
- Tekmira Conference Call And Webcast Advisory: Corporate Update And First Quarter Financial Results 05.09.13 | 08:05 am
- Tekmira Provides Update On U.S. Government Sponsored TKM-Ebola Program 05.08.13 | 08:05 am
- Tekmira's Collaborators At The National Cancer Institute Present Preclinical Data At The Annual Meeting Of The American Association For Cancer Research (AACR) 04.10.13 | 08:04 am
- Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial At American Association For Cancer Research (AACR) Meeting 04.09.13 | 03:04 pm
- Tekmira Provides Corporate Update And Announces Year-End Audited 2012 Results 03.27.13 | 04:03 pm
- 5 Stocks Under $10 Triggering Breakouts 03.21.13 | 01:03 pm
- Tekmira Conference Call And Webcast Advisory: Corporate Update And Year-End 2012 Financial Results 03.20.13 | 04:03 pm
Press Releases for TKMR
Partner Headlines for TKMR
- Tekmira Says Expects to Receive Notice by Sept 30 on DoD's Decision Related to Order on TKM-EBOLA Program - Benzinga 08.31.12 | 04:08 pm
- What Alnylam Doesn't Want You To Know - Seeking Alpha 03.16.12 | 09:03 am
- Tekmira: RNAi Company With Long Term Potential, Short Term Catalysts - Seeking Alpha 03.07.12 | 08:03 am
- Tekmira Provides Periodic Update to Litigation; Alnylam Pharma Files Suit Against Tekmira - Benzinga 01.17.12 | 04:01 pm
- Tekmira Granted an Injunction Against Certain Individuals From AlCana Technologies by the Supreme Court of British Columbia - Benzinga 01.10.12 | 04:01 pm
- Morning Market Losers - Benzinga 12.19.11 | 09:12 am
- Tekmira and Collaborators Present Data at the AACRMeeting on Tekmira's Lead Oncology Product, TKM-PLK1, and an Oncology Product Candidate Targeting Kinase WEE1 - Benzinga 04.04.11 | 04:04 pm
- Tekmira Sues Alnylam Pharmaceuticals for Repeated Misuse of Trade Secrets and Confidential Information - Benzinga 03.16.11 | 04:03 pm
